Research ArticleOpen Access

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on the Electrolytes Changes and Nefropaty

Volume 3 - Issue 4

**Aslan Bilge*¹, Aydın Feray² and Güngör Tayfun³**

Author Information Open or Close
- ¹Anesthesia Clinic Department, Zekai Tahir Burak Training and Research Hospital, Turkey
- ²General Surgery, Zekai Tahir Burak Training and Research Hospital, Turkey
- ³Gynecological Oncologist, Tahir Burak Training and Research Hospital, Turkey
*Corresponding author: Aslan Bilge, Anesthesiologist, Zekai Tahir Burak Training and Research, Hospital, Anesthesia Clinic Department, Talatpaşa Bulvari, 06050, Ankara, Turkey

Received: March 19, 2018; Published: April 09, 2018

DOI: 10.26717/BJSTR.2018.03.000936

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Background

a) Objective:Hyperthermia intraperitoneal chemoprophylaxis (HIPEC) is a treatment of peritoneal carcinomatosis with potential iatrogenic [1-4]. This study was designed to define the effects of HIPEC on renal functions, electrolytes, nefropaty.

b) Methods:We retrospectively reviewed the perioperative care of 20 patients. After cytoreductive surgery (CS), residual tumors were not present in all cases, or were less than or equal to 3 mm (measured in size). Cisplatin 50mg/m2 plus doxorubicin 15mg/m2 was used [1-8]. This is a retrospective study evaluating patients receiving cisplatin with doxorubicin during HIPEC [9,10]. Comorbidities and effects of nephrotoxic drugs were found. Renal function parameters, including serum magnesium levels, were also collected on preoperative and postoperative creatinine levels and on days 1, 5 and 21 posts HIPEC. Perioperative urine output (UO) was also recorded.

d) Findings:20 patients were identified. Based on the RIFLE classification, patients (2.0%) developed acute renal damage (AKI) with HIPEC after cisplatin. The other patient had renal damage. Comparable mean creatinine levels were observed at baseline and on postoperative 21th day after HIPEC (p> 0.05). The incidence of hypomagnesaemia increased to 10% (p = 0.02) on the 5th day and to 5% on the 21th day (p>0.05) after HIPEC.

e) Conclusion:Nephrotoxicity and permanent renal dysfunction may rarely occur in cisplatin therapy with HIPEC. We should closely monitor postoperative Mg levels in patients who have undergone HIPEC administration. Doxsorubicin may have cardiotoxic side effects.

Keywords: Peritoneal Carcinomatosis; HIPEC; Cisplatin; Doxorubicin; Electrolytes

Abbreviations: HIPEC: Hyperthermia Intraperitoneal Chemoprophylaxis; CS: Cytoreductive Surgery; UO: Urine Output; AKI: Acute Renal Damage